12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

Lundbeck, Otsuka Pharmaceutical deal

Lundbeck granted Otsuka co-development and co-commercialization rights to Lu AE58054 in the U.S., Canada, East Asia, major European countries and Nordic countries. The selective serotonin (5-HT6) receptor antagonist is in Phase II testing for Alzheimer's disease...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >